NecstGen and Astraveus explore benchtop CAR-T manufacturing

NecstGen has partnered with Paris-based biotech Astraveus to evaluate the Lakhesys™ Benchtop Cell Factory™, a microfluidic-based platform aiming to simplify and scale CAR-T production. The collaboration will test the system’s potential to reduce cost, footprint, and manual steps in a GMP setting.

The partnership strengthens NecstGen’s role in advancing cell therapy manufacturing and highlights Astraveus’ vision for decentralized, efficient production.

Read more: https://necstgen.com/necstgen-and-astraveus-collaborate-to-evaluate-benchtop-cell-factory-technology-for-scalable-car-t-manufacturing/

Related posts

  • SpectaCell raises €6 million to accelerate drug development

    SpectaCell raises €6 million to accelerate drug development

    For the Leiden Bio Science Park, it is great to see SpectaCell connecting its technology with the biotech ecosystem here in Leiden. SpectaCell will combine its technology development and cell analysis in Ghent with further validation and application within the…

    Read more
  • LUMC opens dedicated CAR-T department

    LUMC opens dedicated CAR-T department

    Leiden University Medical Center (LUMC) has opened a dedicated department for CAR-T cell therapy, bringing care, research and expertise in this rapidly developing field together in one place. The new department, officially opened on 24 September, marks another step in…

    Read more